ACET
Adicet Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.59
+1.70%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+32.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 7, 2026 | Klickstein Lloyd · director, officer: Chief Medical Officer | A-Award | 18,300 | $9.16 |
| Jun 23, 2026 | Grissinger Michael · director | A-Award | 4,200 | $8.10 |
| Jun 23, 2026 | Sinclair Andrew · director | A-Award | 4,200 | $8.10 |
| Jun 23, 2026 | Peng Katie · director | A-Award | 4,200 | $8.10 |
| Jun 23, 2026 | Chodakewitz Jeffrey · director | A-Award | 4,200 | $8.10 |
| Jun 23, 2026 | Schor Chen · director, officer: President & CEO | A-Award | 55,000 | $8.10 |
| Jun 23, 2026 | DUBIN STEVE · director | A-Award | 4,200 | $8.10 |
| Jun 23, 2026 | Aftab Blake · officer: Chief Scientific Officer | A-Award | 55,000 | $8.10 |
| Jun 23, 2026 | Klickstein Lloyd · director | A-Award | 4,200 | $8.10 |
| Apr 13, 2026 | RA CAPITAL MANAGEMENT, L.P. · 10 percent owner | Purchase | 74,577 | $7.04 |
| Apr 13, 2026 | RA CAPITAL MANAGEMENT, L.P. · 10 percent owner | Purchase | 74,751 | $7.27 |
| Apr 13, 2026 | RA CAPITAL MANAGEMENT, L.P. · 10 percent owner | Purchase | 74,268 | $7.21 |
| Apr 9, 2026 | ORBIMED ADVISORS LLC · 10 percent owner | Sale | 40,416 | $6.52 |
| Apr 9, 2026 | ORBIMED ADVISORS LLC · 10 percent owner | Sale | 32,523 | $6.29 |
| Apr 9, 2026 | ORBIMED ADVISORS LLC · 10 percent owner | Sale | 29,319 | $6.53 |
| Apr 9, 2026 | ORBIMED ADVISORS LLC · 10 percent owner | Sale | 2,400 | $6.38 |
| Mar 27, 2026 | Healey Don · officer: Chief Technology Officer | A-Award | 43,361 | $6.81 |
| Mar 27, 2026 | Schor Chen · director, officer: President & CEO | A-Award | 468,555 | $6.81 |
| Mar 27, 2026 | Maltzman Julia D. · officer: Chief Medical Officer | A-Award | 72,555 | $6.81 |
| Mar 27, 2026 | Aftab Blake · officer: Chief Scientific Officer | A-Award | 72,555 | $6.81 |
| Mar 27, 2026 | Harvey Brian Nicholas · officer: Chief Financial Officer | A-Award | 43,361 | $6.81 |
| Jan 27, 2026 | Schor Chen · director, officer: President & CEO | F-InKind | 1,755 | $8.44 |
| Jan 27, 2026 | Healey Don · officer: Chief Technology Officer | F-InKind | 535 | $8.44 |
| Jan 27, 2026 | Aftab Blake · officer: Chief Scientific Officer | F-InKind | 535 | $8.44 |
| Jan 27, 2026 | Harvey Brian Nicholas · officer: Chief Financial Officer | F-InKind | 546 | $8.44 |
| Oct 10, 2025 | ORBIMED ADVISORS LLC · 10 percent owner | Purchase | 3,500,000 | $1.00 |
| Oct 10, 2025 | ORBIMED ADVISORS LLC · 10 percent owner | Purchase | 1,500,000 | $1.00 |
| Jun 13, 2025 | Sinclair Andrew · director | A-Award | 26,400 | $0.78 |
| Jun 13, 2025 | Peng Katie · director | A-Award | 5,900 | $0.00 |
| Jun 13, 2025 | Peng Katie · director | A-Award | 26,400 | $0.78 |
Institutional positioning
13F filings over the trailing two quarters
New 15Increased 12Reduced 10Sold out 49
| Filer | Action | Shares | Filed |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Increased | 1,182,624 | May 15, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 1,027,944 | May 15, 2026 |
| FRANKLIN RESOURCES INC | Unchanged | 626,571 | May 13, 2026 |
| CITADEL ADVISORS LLC | Increased | 466,248 | Sep 2, 2026 |
| CITADEL ADVISORS LLC | Increased | 381,823 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 336,524 | May 15, 2026 |
| WOODLINE PARTNERS LP | Reduced | 313,124 | May 15, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Unchanged | 274,375 | May 15, 2026 |
| PROSIGHT MANAGEMENT, LP | Unchanged | 250,244 | May 15, 2026 |
| GOLDMAN SACHS GROUP INC | New Position | 234,510 | Mar 25, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Reduced | 232,591 | May 14, 2026 |
| STONEPINE CAPITAL MANAGEMENT, LLC | Increased | 221,955 | May 14, 2026 |
| ALYESKA INVESTMENT GROUP, L.P. | Unchanged | 203,799 | May 15, 2026 |
| CARLYLE GROUP INC. | Unchanged | 184,295 | May 8, 2026 |
| NEXTBio Capital Management LP | Unchanged | 157,827 | May 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 7, 2026